Does your AMH level really predict your fertility?

AMH: a plain-language definition of the hormone

AMH is a hormone secreted by granulosa cells of preantral and small antral follicles in the ovaries. It reflects ovarian reserve — specifically egg quantity, not egg quality. Think of it as a headcount of the bench players your ovaries have available to develop in future cycles: more follicles on deck, higher AMH; fewer follicles, lower AMH. It does not tell you whether you are ovulating this month, whether you can conceive right now, or whether a pregnancy will be healthy. It is one piece of the puzzle, most meaningful when paired with age, antral follicle count (AFC), and reproductive history. As a brief aside, AMH is also produced by Sertoli cells in males before puberty and is used in pediatric endocrine evaluations.

What AMH reflects about ovarian reserve

Your ovaries hold a finite pool of follicles from birth. Each cycle, a subset steps forward. AMH acts like a dimmer switch inside the ovary, helping regulate how many follicles are recruited at once. When many small follicles are on deck, AMH runs higher. As the pool shrinks with age, AMH falls. Critically, AMH does not predict egg quality — quality is primarily age-dependent and is not captured by this marker.

Several factors shape how the number reads. In polycystic ovary syndrome (PCOS), more small follicles produce AMH, so levels often read high. Combined hormonal contraception can suppress AMH modestly during use, with levels generally rebounding after stopping. During pregnancy and the postpartum period, AMH tends to dip as the ovary goes quiet. After menopause, AMH is usually undetectable because the follicle pool is essentially gone.

On a population level, lower AMH in midlife is associated with an earlier age at menopause, though prediction windows for individuals remain wide. Conditions like PCOS, often linked with higher AMH in youth, carry their own metabolic considerations that intersect with long-term health.

One important measurement caveat: assay methods differ between labs, and results are not perfectly interchangeable across platforms. Units may be reported as ng/mL or pmol/L, and clinical thresholds are assay-specific. Trends over time on the same platform, interpreted alongside age and ultrasound, matter more than any single number.

Reading your AMH number against age

Reference ranges are built from large populations, not customized to any individual. A "normal" AMH means you fall within the range of many others in your age bracket — it is not a guarantee of easy conception, nor does a low value automatically mean you will not conceive. In general, values above 1 ng/mL are considered adequate during the reproductive years, but ranges vary by lab and assay platform. The same blood sample can read differently on different platforms; that is a known limitation of current assays, not an error.

There is no universal optimal AMH for natural conception. What matters is context: your age, menstrual regularity, antral follicle count, partner factors, and goals. AMH correlates with expected egg yield in IVF stimulation, where it helps with dosing and risk assessment — but outside of assisted reproduction, a single number carries limited standalone meaning.

Low AMH

A lower AMH usually reflects a smaller follicle bench, a pattern that naturally emerges with age. It can also follow ovarian surgery, chemotherapy or radiation, or conditions like endometriosis that affect ovarian tissue. Smoking is associated with lower AMH, and obesity has been linked to modestly lower values in some studies, though effects vary. Low AMH does not determine egg quality, which is heavily age-dependent. Many people with low AMH still ovulate regularly and conceive. In assisted reproduction, a low AMH can predict a lower egg yield, which helps set realistic expectations and tailor medication dosing. If a result is unexpectedly low, consider timing: recent hormonal contraception use or assay differences can shift numbers. A repeat on the same platform, paired with antral follicle count, often brings clarity.

Normal AMH

A result within the age-appropriate reference range indicates a follicle pool consistent with peers of the same age. Because ranges are age-dependent and assay-specific, "normal" should always be interpreted relative to both. AFC pairing adds confidence: when AFC and AMH align, the estimate of reserve is more reliable. There is no single normal that guarantees any particular fertility outcome — regularity of cycles, age, and overall reproductive history remain essential context.

High AMH

A higher AMH often means many small follicles are in reserve. In PCOS, this is common and may accompany irregular cycles or signs of androgen excess. In fertility treatment, a high AMH can predict a strong response to ovarian stimulation, which is useful for dosing and for assessing the risk of ovarian hyperstimulation syndrome. At younger ages, high AMH with regular cycles and no symptoms may simply reflect robust reserve. An ultrasound antral follicle count can confirm whether many small follicles are present. If testosterone or LH are elevated and cycles are irregular, the pattern leans toward PCOS. Rarely, markedly elevated AMH can appear in granulosa cell tumors — but that interpretation requires other clinical red flags and is not made from an isolated AMH result. If AMH was measured while on hormonal contraception or soon after pregnancy, a repeat off hormones or later in the postpartum period can recalibrate expectations.

Factors that influence AMH measurements between draws

AMH is relatively stable compared with FSH or estradiol — it does not swing widely across a single cycle — but several factors can shift the reading or affect the follicle environment it reflects.

• Assay platform: Values are not interchangeable across laboratory platforms. Comparing results from different assays can be misleading; trend monitoring requires the same platform each time.
• Hormonal contraception: Combined hormonal contraceptives suppress AMH during use. Levels generally rebound after stopping, so a result taken while on contraception may underestimate underlying reserve.
• Pregnancy and postpartum: AMH tends to be lower during pregnancy and in the immediate postpartum period, likely reflecting reduced ovarian activity while the placenta manages hormonal output.
• Ovarian surgery, endometriosis, chemotherapy, and pelvic radiation: These can reduce ovarian reserve directly, resulting in persistently lower AMH.
• Obesity: Associated with modestly lower AMH values in some studies, though the effect size varies.
• Insulin resistance in PCOS: Affects ovulatory function and the hormonal environment, though it does not directly raise or lower AMH itself.

No intervention has been shown to meaningfully increase ovarian reserve. This section describes what shifts the reading or the follicle environment — not actions that improve AMH.

Markers that read AMH in context

AMH is most informative when interpreted alongside other markers. The following tests each add a distinct dimension:

• Follicle-stimulating hormone (FSH) — Day-3 FSH measures how hard the brain is working to recruit a follicle; high FSH combined with low AMH indicates the ovary needs more hormonal coaching, confirming reduced reserve from two directions.
• Luteinizing hormone (LH) — LH paired with AMH helps separate PCOS-pattern ovarian dysfunction (high LH + high AMH) from age-related decline (normal or low LH + low AMH).
• Estradiol — Day-3 estradiol completes the baseline ovarian reserve panel; an elevated Day-3 estradiol with low FSH can artificially suppress FSH and mask poor reserve.
• Sex hormone-binding globulin (SHBG) — SHBG helps characterize the PCOS metabolic picture when AMH is high and androgen excess is suspected; low SHBG combined with high AMH is a classic insulin-driven PCOS pattern.
• Total testosterone — Total testosterone completes the androgen picture in high-AMH/PCOS presentations; elevated testosterone combined with high AMH confirms androgen excess as the clinical context.

Antral follicle count by transvaginal ultrasound is not a blood biomarker but is the most direct structural correlate of AMH. When AFC and AMH align, confidence in the reserve estimate rises considerably.

Why AMH moves on a yearly timeline

AMH reflects a reserve that turns over on a timescale of years, not months. Retesting sooner than 12 months in a healthy adult usually measures platform noise rather than meaningful biological change. A minimum retest interval of 12 months is appropriate for routine monitoring, and results are only comparable when drawn on the same assay platform — values across platforms are not interchangeable.

More frequent retesting is warranted in specific clinical situations:

• Before fertility preservation, to anchor the decision with a current baseline
• During monitoring of the effects of chemotherapy or radiation on ovarian reserve
• When a result is unexpectedly discordant with antral follicle count, prompting a same-platform repeat to distinguish biology from assay variation

Outside these scenarios, quarterly or even semi-annual retesting adds little clinical information and risks over-interpreting normal assay variability as a trend.

When AMH results warrant a fertility consultation

AMH gives you a trend line, not a verdict. A result that surprises you — high, low, or simply unexpected given your age — is a prompt for a conversation, not a conclusion. Pair the number with how regularly you cycle, your age, antral follicle count, and any relevant history (ovarian surgery, endometriosis, prior chemotherapy) before drawing meaning from it.

Consider a fertility consultation when:

• AMH is low for your age and you are considering pregnancy in the near or medium term
• AMH is markedly elevated alongside irregular cycles, signs of androgen excess, or metabolic concerns suggesting PCOS
• You are considering fertility preservation and want to understand your current reserve
• AMH and AFC are discordant, or a result seems inconsistent with your clinical picture
• You have a history of ovarian surgery, endometriosis, or cancer treatment that may have affected reserve

Testing AMH is worth doing because it turns a vague sense of "where am I?" into a data point you can act on — adjusting timelines, aligning resources, and avoiding surprises. It is most powerful as part of a comprehensive picture that includes cycle history, ultrasound, and a few targeted labs reviewed with a clinician.

At Superpower, AMH sits within a broader biomarker panel designed to map reproductive and metabolic health together. The goal is not a perfect number — it is personalized, evidence-based clarity so you can make decisions that fit your body and your timeline. Learn more about the approach at our manifesto.